Lenvima capsules 4 mg for unresectable thyroid carcinoma (lenvatinib mesylate, lenvatinib mesilate)

General information on Japanese Lenvima capsules 4 mg for unresectable thyroid carcinoma (lenvatinib mesylate, lenvatinib mesilate)

Package details: 20 capsules

Manufacturer: Eisai Co., Ltd., Japan

Active ingredients: lenvatinib mesylate (chemical formula C22H23ClN4O7S)

Medical effect: Lenvima capsules are effective for the treatment of unresectable thyroid carcinoma.

Contraindications and precautions: do not use for the pregnant, possibly pregnant or breastfeeding women.

The patient’s blood pressure should be measured periodically.

As this medicine may cause dizziness or fatigue, please take care when operating dangerous mechanism, driving a car or working on heights.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

Dosage and administration of Lenvima capsules 4 mg from Japan for unresectable thyroid carcinoma (lenvatinib mesylate, lenvatinib mesilate)

For adults, take 24 mg of the active ingredient at a time, once a day. The doctor in charge may decrease the dosage according to patient’s symptoms. Please note that this medication contains 4 mg of the active ingredient in 1 capsule.

How effective are Lenvima capsules 4 mg from Japan for unresectable thyroid carcinoma (lenvatinib mesylate, lenvatinib mesilate)?

Lenvima capsules contain lenvatinib mesilate, a novel anti-tumor agent developed by Japanese pharmaceutical maker Eisai Co. It works by inhibiting kinases involved in in cancerogenic signaling pathways and, thereby, inhibiting tumor proliferation and vascularization. Lenvatinib is absorbed quickly, reaches peak blood plasma concentrations within 1-4 hours (3-7 if taken with food) and has a high bioavailability profile (about 85%).

Who should use Lenvima capsules 4 mg from Japan?

Lenvima capsules are effective for the treatment of radically unresectable thyroid carcinoma. Studies proved that lenvatinib significantly improves progression-free survival (18.3 months in the lenvatinib group and 3.6 months in the placebo group) and the response rate (64.8% in the lenvatinib group and 1.5% in the placebo group), though the adverse effects, especially blood pressure changes, should be monitored (M. Schlumberger, M. Tahara et al. “Lenvatinib versus placebo in radioiodine-refractory thyroid cancer”. The New England Journal of Medicine, 2015, 12; 372(7): 621-30).